CALQUENCE COMPRIMIDOS

ਉਤਪਾਦ ਝਲਕ

About CALQUENCE

CALQUENCE is a medication containing the active ingredient acalabrutinib, classified as Kinase Inhibitor. Acalabrutinib, sold under the brand name Calquence, is an anti-cancer medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. It may be used both in relapsed as well as in treatment-naive settings.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult.
• Use only as directed on the product label or by a healthcare professional.
• Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

acalabrutinib, the active ingredient in CALQUENCE, belongs to the Kinase Inhibitor class. 1 INDICATIONS AND USAGE CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). (1. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking CALQUENCE. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use CALQUENCE for extended periods without medical advice.